Compare BHE & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHE | PGEN |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | 11840 | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1996 | 2013 |
| Metric | BHE | PGEN |
|---|---|---|
| Price | $81.97 | $7.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $86.00 | $13.65 |
| AVG Volume (30 Days) | 334.1K | ★ 4.7M |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.91 | 0.03 |
| Revenue | ★ $2,659,108,000.00 | $230,981,000.00 |
| Revenue This Year | $12.94 | $2,365.68 |
| Revenue Next Year | $7.05 | $85.75 |
| P/E Ratio | ★ $89.19 | $253.33 |
| Revenue Growth | ★ 0.11 | N/A |
| 52 Week Low | $35.97 | $3.04 |
| 52 Week High | $100.41 | $8.98 |
| Indicator | BHE | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 52.60 |
| Support Level | $81.54 | $6.41 |
| Resistance Level | $87.58 | $8.98 |
| Average True Range (ATR) | 2.62 | 0.51 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 44.60 | 28.77 |
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.